Heart transplantation in patients with treated breast carcinoma.
Since 1987, five women with end-stage cardiomyopathy and a history of treated breast carcinoma have undergone transplantation at our institution. All patients underwent extensive multidisciplinary pretransplantation evaluation to rule out metastatic disease. Disease-free interval before heart transplantation ranged from 5 to 11 years (mean, 7.6 years). All patients received immunosuppression in accordance with a standard protocol of rabbit antithymocyte globulin, cyclosporine, prednisone, and azathioprine. Mean postoperative follow-up is 49 months. All patients are alive and have no symptoms 18 to 73 months after transplantation. In carefully selected patients with a history of breast carcinoma, heart transplantation can be performed with good functional results and satisfactory late survival.
Section of Cardiovascular and Thoracic Surgery, University of Arizona Health Sciences Center, Tucson 85724.
L J
LJ
Rosado
J C
JC
Wild
C L
CL
Huston
G K
GK
Sethi
J G
JG
Copeland
D000328:Adult; D001706:Biopsy; D001943:Breast Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D003131:Combined Modality Therapy; D004699:Endocardium / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy / Q000473:pathology; D006333:Heart Failure / Q000473:pathology / Q000601:surgery*; D016027:Heart Transplantation / Q000473:pathology; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D015411:Mastectomy, Modified Radical; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D010348:Patient Care Team; D011183:Postoperative Complications / Q000473:pathology / Q000601:surgery*
D007166:Immunosuppressive Agents